Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies

Handbook of Clinical Neurology

Volumn 144, Issue , 2017, Pages 15-28

  Ross, Christopher A ^a   Kronenbuerger, Martin ^a   Duan, Wenzhen ^a   Margolis, Russell L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aggregation; antisense; gene transcription; Huntingtin; inclusion

Indexed keywords

HUNTINGTIN;

ANIMAL; DISEASE MODEL; GENETICS; HUNTINGTON CHOREA; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PROTEIN PROCESSING; TRINUCLEOTIDE REPEAT;

ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 85037033231     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801893-4.00002-X     Document Type: Chapter

References (194)

1. Aiken, C.T., Steffan, J.S., Guerrero, C.M., et al. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284 (2009), 29427–29436.
2. Albin, R.L., Young, A.B., Penney, J.B., The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989), 366–375.
3. Andre, R., Carty, L., Tabrizi, S.J., Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. Curr Opin Pharmacol 26 (2015), 33–38.
4. Apostol, B.L., Simmons, D.A., Zuccato, C., et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 39 (2008), 8–20.
5. Atwal, R.S., Desmond, C.R., Caron, N., et al. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7 (2011), 453–460.
6. Aziz, N.A., Pijl, H., Frolich, M., et al. Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clin Endocrinol (Oxf) 73 (2010), 206–211.
7. Aziz, N.A., Pijl, H., Frolich, M., et al. Systemic energy homeostasis in Huntington's disease patients. J Neurol Neurosurg Psychiatry 81 (2010), 1233–1237.
8. Banez-Coronel, M., Porta, S., Kagerbauer, B., et al. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet, 8, 2012, e1002481.
9. Banez-Coronel, M., Ayhan, F., Tarabochia, A.D., et al. RAN translation in Huntington disease. Neuron 88 (2015), 667–677.
10. Benn, C.L., Sun, T., Sadri-Vakili, G., et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 28 (2008), 10720–10733.
11. Bennett, E.J., Bence, N.F., Jayakumar, R., et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17 (2005), 351–365.
12. Bennett, E.J., Shaler, T.A., Woodman, B., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448 (2007), 704–708.
13. Bjorkqvist, M., Wild, E.J., Thiele, J., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205 (2008), 1869–1877.
14. Boudreau, R.L., Mcbride, J.L., Martins, I., et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17 (2009), 1053–1063.
15. Bowles, K.R., Jones, L., Kinase signalling in Huntington's disease. J Huntingtons Dis 3 (2014), 89–123.
16. Bradford, J., Shin, J.Y., Roberts, M., et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 285 (2010), 10653–10661.
17. Brustovetsky, N., Mutant huntingtin and elusive defects in oxidative metabolism and mitochondrial calcium handling. Mol Neurobiol 53 (2016), 2944–2953.
18. Butler, R., Bates, G.P., Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7 (2006), 784–796.
19. Carroll, J.B., Bates, G.P., Steffan, J., et al. Treating the whole body in Huntington's disease. Lancet Neurol 14 (2015), 1135–1142.
20. Cattaneo, E., Zuccato, C., Tartari, M., Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6 (2005), 919–930.
21. Caviston, J.P., Holzbaur, E.L., Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19 (2009), 147–155.
22. Chopra, V., Fox, J.H., Lieberman, G., et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A 104 (2007), 16685–16689.
23. Chung, D.W., Rudnicki, D.D., Yu, L., et al. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet 20 (2011), 3467–3477.
24. Ciechanover, A., Kwon, Y.T., Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med, 47, 2015, e147.
25. Cleary, J.D., Ranum, L.P., Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr Opin Genet Dev 26 (2014), 6–15.
26. Cowan, C.M., Raymond, L.A., Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 75 (2006), 25–71.
27. Crook, Z.R., Housman, D.E., Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines. J Huntingtons Dis 2 (2013), 405–436.
28. Cui, L., Jeong, H., Borovecki, F., et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127 (2006), 59–69.
29. Culver, B.P., Savas, J.N., Park, S.K., et al. Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem 287 (2012), 21599–21614.
30. De Mezer, M., Wojciechowska, M., Napierala, M., et al. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res 39 (2011), 3852–3863.
31. Desmond, C.R., Atwal, R.S., Xia, J., et al. Identification of a karyopherin beta1/beta2 proline-tyrosine nuclear localization signal in huntingtin protein. J Biol Chem 287 (2012), 39626–39633.
32. Dickey, A., Pineda, V., Tsunemi, T., PPARdelta repression in Huntington's disease and its essential role in CNS translate into a potent agonist therapy. Nat Med 22 (2016), 37–45.
33. Difiglia, M., Sapp, E., Chase, K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997), 1990–1993.
34. Difiglia, M., Sena-Esteves, M., Chase, K., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104 (2007), 17204–17209.
35. Duan, W., Guo, Z., Jiang, H., et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100 (2003), 2911–2916.
36. Duan, W., Peng, Q., Masuda, N., et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30 (2008), 312–322.
37. Duan, W., Jiang, M., Jin, J., Metabolism in HD: still a relevant mechanism?. Mov Disord 29 (2014), 1366–1374.
38. Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15 (2008), 558–566.
39. Fernandez-Nogales, M., Cabrera, J.R., Santos-Galindo, M., et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20 (2014), 881–885.
40. Fox, J.H., Connor, T., Stiles, M., et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem 286 (2011), 18320–18330.
41. Gabery, S., Murphy, K., Schultz, K., et al. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 120 (2010), 777–788.
42. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium, Identification of genetic factors that modify clinical onset of Huntington's disease. Cell 162 (2015), 516–526.
43. Gharami, K., Xie, Y., An, J.J., et al. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem 105 (2008), 369–379.
44. Graham, R.K., Deng, Y., Slow, E.J., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125 (2006), 1179–1191.
45. Gu, X., Greiner, E.R., Mishra, R., et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64 (2009), 828–840.
46. Guo, J.L., Lee, V.M., Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20 (2014), 130–138.
47. Gusella, J.F., Macdonald, M.E., Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci 31 (2006), 533–540.
48. HD iSPC Consortium, Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11 (2012), 264–278.
49. Herbst, M., Wanker, E.E., Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener Dis 4 (2007), 254–260.
50. Herskovits, A.Z., Guarente, L., Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 23 (2013), 746–758.
51. Hockly, E., Richon, V.M., Woodman, B., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100 (2003), 2041–2046.
52. Hodges, A., Strand, A.D., Aragaki, A.K., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15 (2006), 965–977.
53. Holmes, S.E., O'Hearn, E., Rosenblatt, A., et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 29 (2001), 377–378.
54. Hu, J., Matsui, M., Gagnon, K.T., et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27 (2009), 478–484.
55. Huang, B., Wei, W., Wang, G., et al. Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron 85 (2015), 1212–1226.
56. Hubbert, C., Guardiola, A., Shao, R., et al. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002), 455–458.
57. Huntington Study Group, A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 (2001), 397–404.
58. Huntington's Disease Collaborative Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993), 971–983.
59. Jamwal, S., Kumar, P., Antidepressants for neuroprotection in Huntington's disease: A review. Eur J Pharmacol, 2015.
60. Jeong, H., Then, F., Melia, T.J. Jr., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137 (2009), 60–72.
61. Jeong, H., Cohen, D.E., Cui, L., et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18 (2012), 159–165.
62. Jiang, H., Poirier, M.A., Liang, Y., et al. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis 23 (2006), 543–551.
63. Jiang, M., Wang, J., Fu, J., et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 18 (2012), 153–158.
64. Jiang, M., Peng, Q., Liu, X., et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 22 (2013), 2462–2470.
65. Jiang, M., Zheng, J., Peng, Q., et al. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol 1 (2014), 1047–1052.
66. Jimenez-Sanchez, M., Lam, W., Hannus, M., et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat Chem Biol 11 (2015), 347–354.
67. Jin, J., Albertz, J., Guo, Z., et al. Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem 125 (2013), 410–419.
68. Johri, A., Calingasan, N.Y., Hennessey, T.M., et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 21 (2012), 1124–1137.
69. Ju, T.C., Chen, H.M., Lin, J.T., et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 194 (2011), 209–227.
70. Juenemann, K., Schipper-Krom, S., Wiemhoefer, A., et al. Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes. J Biol Chem 288 (2013), 27068–27084.
71. Kaganovich, D., Kopito, R., Frydman, J., Misfolded proteins partition between two distinct quality control compartments. Nature 454 (2008), 1088–1095.
72. Kazantsev, A.G., Hersch, S.M., Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 83 (2007), 249–259.
73. Kim, M., Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion 7 (2013), 221–228.
74. Kim, M.W., Chelliah, Y., Kim, S.W., et al. Secondary structure of Huntingtin amino-terminal region. Structure 17 (2009), 1205–1212.
75. Kim, J., Moody, J.P., Edgerly, C.K., et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet 19 (2010), 3919–3935.
76. Kincaid, B., Bossy-Wetzel, E., Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front Aging Neurosci, 5, 2013, 48.
77. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74 (2012), 1031–1044.
78. Kratter, I.H., Zehed, H., Lau, A., et al. Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126 (2016), 3585–3597.
79. Kremer, H.P., Roos, R.A., Dingjan, G., et al. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 49 (1990), 371–382.
80. Kremer, H.P., Roos, R.A., Dingjan, G.M., et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 132 (1991), 101–104.
81. La Spada, A.R., Something wicked this way comes: huntingtin. Nat Neurosci 17 (2014), 1014–1015.
82. Labbadia, J., Morimoto, R.I., Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38 (2013), 378–385.
83. Lai, A.Y., Lan, C.P., Hasan, S., et al. scyllo-Inositol promotes robust mutant Huntingtin protein degradation. J Biol Chem 289 (2014), 3666–3676.
84. Landles, C., Sathasivam, K., Weiss, A., et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285 (2010), 8808–8823.
85. Landwehrmeyer, G.B., Dubois, B., De Yebenes, J.G., et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 62 (2007), 262–272.
86. Lee, J.H., Sowada, M.J., Boudreau, R.L., et al. Rhes suppression enhances disease phenotypes in Huntington's disease mice. J Huntingtons Dis 3 (2014), 65–71.
87. Legleiter, J., Lotz, G.P., Miller, J., et al. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem 284 (2009), 21647–21658.
88. Legleiter, J., Mitchell, E., Lotz, G.P., et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285 (2010), 14777–14790.
89. Li, S.H., Li, X.J., Huntingtin–protein interactions and the pathogenesis of Huntington's disease. Trends Genet 20 (2004), 146–154.
90. Li, W., Serpell, L.C., Carter, W.J., et al. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J Biol Chem 281 (2006), 15916–15922.
91. Lin, J., Wu, P.H., Tarr, P.T., et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119 (2004), 121–135.
92. Liu, Y.J., Chern, Y., AMPK-mediated regulation of neuronal metabolism and function in brain diseases. J Neurogenet 29 (2015), 50–58.
93. Lunkes, A., Lindenberg, K.S., Ben-Haiem, L., et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10 (2002), 259–269.
94. Margolis, R.L., O'Hearn, E., Rosenblatt, A., et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 50 (2001), 373–380.
95. Margulis, J., Finkbeiner, S., Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease. Front Cell Neurosci, 8, 2014, 218.
96. Martinez-Vicente, M., Talloczy, Z., Wong, E., et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 13 (2010), 567–576.
97. Mielcarek, M., Benn, C., Butler, R., et al. Genetic knock-down of HDAC4 improves motor impairment in the R6/2 mouse model of HD. J Neurol Neurosurg Psychiatry, 79, 2008 A7, abstract B5.
98. Miller, J., Arrasate, M., Shaby, B.A., et al. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington's disease molecular pathogenesis. J Neurosci 30 (2010), 10541–10550.
99. Molero, A.E., Gokhan, S., Gonzalez, S., et al. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci U S A 106 (2009), 21900–21905.
100. Mrzljak, L., Munoz-Sanjuan, I., Therapeutic strategies for Huntington's disease. Curr Top Behav Neurosci 22 (2015), 161–201.
101. Myers, R.H., Sax, D.S., Koroshetz, W.J., et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 48 (1991), 800–804.
102. Mykowska, A., Sobczak, K., Wojciechowska, M., et al. CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res 39 (2011), 8938–8951.
103. Nagai, Y., Inui, T., Popiel, H.A., et al. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 14 (2007), 332–340.
104. Naia, L., Rego, A.C., Sirtuins: double players in Huntington's disease. Biochim Biophys Acta 1852 (2015), 2183–2194.
105. Nalavade, R., Griesche, N., Ryan, D.P., et al. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis, 4, 2013, e752.
106. Nucifora, F.C. Jr., Sasaki, M., Peters, M.F., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001), 2423–2428.
107. Nucifora, L.G., Burke, K.A., Feng, X., et al. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 287 (2012), 16017–16028.
108. Ochaba, J., Lukacsovich, T., Csikos, G., et al. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A 111 (2014), 16889–16894.
109. Okamoto, S., Pouladi, M.A., Talantova, M., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15 (2009), 1407–1413.
110. Olshina, M.A., Angley, L.M., Ramdzan, Y.M., et al. Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 285 (2010), 21807–21816.
111. Pallos, J., Bodai, L., Lukacsovich, T., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 17 (2008), 3767–3775.
112. Pavese, N., Gerhard, A., Tai, Y.F., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66 (2006), 1638–1643.
113. Perrin, V., Regulier, E., Abbas-Terki, T., et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15 (2007), 903–911.
114. Petersen, A., Gil, J., Maat-Schieman, M.L., et al. Orexin loss in Huntington's disease. Hum Mol Genet 14 (2005), 39–47.
115. Pfister, E.L., Zamore, P.D., Huntington's disease: silencing a brutal killer. Exp Neurol 220 (2009), 226–229.
116. Pfister, E.L., Kennington, L., Straubhaar, J., et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19 (2009), 774–778.
117. Plotkin, J.L., Day, M., Peterson, J.D., et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 83 (2014), 178–188.
118. Poirier, M.A., Jiang, H., Ross, C.A., A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 14 (2005), 765–774.
119. Powers, W.J., Videen, T.O., Markham, J., et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A 104 (2007), 2945–2949.
120. Ramdzan, Y.M., Nisbet, R.M., Miller, J., et al. Conformation sensors that distinguish monomeric proteins from oligomers in live cells. Chem Biol 17 (2010), 371–379.
121. Ratovitski, T., Nakamura, M., D'ambola, J., et al. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 6 (2007), 2970–2981.
122. Ratovitski, T., Gucek, M., Jiang, H., et al. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284 (2009), 10855–10867.
123. Ravikumar, B., Imarisio, S., Sarkar, S., et al. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci 121 (2008), 1649–1660.
124. Reiner, A., Dragatsis, I., Zeitlin, S., et al. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 28 (2003), 259–276.
125. Ren, Y., Jiang, H., Yang, F., et al. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J Biol Chem 284 (2009), 4009–4017.
126. Renna, M., Jimenez-Sanchez, M., Sarkar, S., et al. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 285 (2010), 11061–11067.
127. Rockabrand, E., Slepko, N., Pantalone, A., et al. The first 17 amino acids of huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16 (2007), 61–77.
128. Rosenblatt, A., Liang, K.Y., Zhou, H., et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66 (2006), 1016–1020.
129. Ross, C.A., Cleveland, D.W., Intercellular miscommunication in polyglutamine pathogenesis. Nat Neurosci 9 (2006), 1205–1206.
130. Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. Nat Med 10:Suppl (2004), S10–S17.
131. Ross, C.A., Poirier, M.A., Opinion: What is the role of protein aggregation in neurodegeneration?. Nat Rev Mol Cell Biol 6 (2005), 891–898.
132. Rudnicki, D.D., Holmes, S.E., Lin, M.W., et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 61 (2007), 272–282.
133. Rudnicki, D.D., Margolis, R.L., Pearson, C.E., et al. Diced triplets expose neurons to RISC. PLoS Genet, 8, 2012, e1002545.
134. Sadri-Vakili, G., Cha, J.H., Mechanisms of disease: histone modifications in Huntington's disease. Nat Clin Pract Neurol 2 (2006), 330–338.
135. Sapp, E., Kegel, K.B., Aronin, N., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60 (2001), 161–172.
136. Savas, J.N., Ma, B., Deinhardt, K., et al. A role for Huntington disease protein in dendritic RNA granules. J Biol Chem 285 (2010), 13142–13153.
137. Schapira, A.H., Olanow, C.W., Greenamyre, J.T., et al. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384 (2014), 545–555.
138. Schilling, B., Gafni, J., Torcassi, C., et al. Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 281 (2006), 23686–23697.
139. Schilling, G., Klevytska, A., Tebbenkamp, A.T., et al. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 66 (2007), 313–320.
140. Schwarcz, R., Guidetti, P., Sathyasaikumar, K.V., et al. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90 (2010), 230–245.
141. Seixas, A.I., Holmes, S.E., Takeshima, H., et al. Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. Ann Neurol 71 (2012), 245–257.
142. Sepers, M.D., Raymond, L.A., Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. Drug Discov Today 19 (2014), 990–996.
143. Shao, J., Diamond, M.I., Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16:2 (2007), R115–R123.
144. Shin, J.Y., Fang, Z.H., Yu, Z.X., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171 (2005), 1001–1012.
145. Simmons, D.A., Rex, C.S., Palmer, L., et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A 106 (2009), 4906–4911.
146. Soneson, C., Fontes, M., Zhou, Y., et al. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis 40 (2010), 531–543.
147. Song, W., Chen, J., Petrilli, A., et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 17 (2011), 377–382.
148. Steffan, J.S., Bodai, L., Pallos, J., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001), 739–743.
149. Subramaniam, S., Sixt, K.M., Barrow, R., et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324 (2009), 1327–1330.
150. Sun, X., Marque, L.O., Cordner, Z., et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet 23 (2014), 6302–6317.
151. Sun, X., Li, P.P., Zhu, S., et al. Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65. Sci Rep, 5, 2015, 12521.
152. Tai, Y.F., Pavese, N., Gerhard, A., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130 (2007), 1759–1766.
153. Tam, S., Spiess, C., Auyeung, W., et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16 (2009), 1279–1285.
154. Tang, T.S., Guo, C., Wang, H., et al. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci 29 (2009), 1257–1266.
155. Tang, C.C., Feigin, A., Ma, Y., et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest 123 (2013), 4076–4088.
156. Thakur, A.K., Jayaraman, M., Mishra, R., et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16 (2009), 380–389.
157. Thomas, E.A., Coppola, G., Desplats, P.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 105 (2008), 15564–15569.
158. Thompson, L.M., Aiken, C.T., Kaltenbach, L.S., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187 (2009), 1083–1099.
159. Thornton, C.A., Myotonic dystrophy. Neurol Clin 32 (2014), 705–719 vii.
160. Tobin, A.J., Signer, E.R., Huntington's disease: the challenge for cell biologists. Trends Cell Biol 10 (2000), 531–536.
161. Trepte, P., Strempel, N., Wanker, E.E., Spontaneous self-assembly of pathogenic huntingtin exon 1 protein into amyloid structures. Essays Biochem 56 (2014), 167–180.
162. Truant, R., Atwal, R.S., Desmond, C., et al. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J 275 (2008), 4252–4262.
163. Tsunemi, T., Ashe, T.D., Morrison, B.E., et al. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 4 (2012), 142–197.
164. Tsvetkov, A.S., Arrasate, M., Barmada, S., et al. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol 9 (2013), 586–592.
165. Vacher, C., Garcia-Oroz, L., Rubinsztein, D.C., Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 14 (2005), 3425–3433.
166. Vilchez, D., Saez, I., Dillin, A., The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun, 5, 2014, 5659.
167. Vonsattel, J.P., Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115 (2008), 55–69.
168. Waldron-Roby, E., Ratovitski, T., Wang, X., et al. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32 (2012), 183–193.
169. Walker, F.O., Huntington's disease. Lancet 369 (2007), 218–228.
170. Wang, J., Wang, C.E., Orr, A., et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 180 (2008), 1177–1189.
171. Wang, Y., Lin, F., Qin, Z.H., The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. Neurosci Bull 26 (2010), 153–162.
172. Wang, N., Gray, M., Lu, X.H., et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 20 (2014), 536–541.
173. Wang, R., Ross, C.A., Cai, H., et al. Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients. Front Physiol, 5, 2014, 231.
174. Warby, S.C., Chan, E.Y., Metzler, M., et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14 (2005), 1569–1577.
175. Warby, S.C., Doty, C.N., Graham, R.K., et al. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40 (2009), 121–127.
176. Watkin, E.E., Arbez, N., Waldron-Roby, E., et al. Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity. PLoS One, 9, 2014, e88284.
177. Weydt, P., Pineda, V.V., Torrence, A.E., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4 (2006), 349–362.
178. White, J.K., Auerbach, W., Duyao, M.P., et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17 (1997), 404–410.
179. Wilburn, B., Rudnicki, D.D., Zhao, J., et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron 70 (2011), 427–440.
180. Wild, E.J., Tabrizi, S.J., Targets for future clinical trials in Huntington's disease: what's in the pipeline?. Mov Disord 29 (2014), 1434–1445.
181. Wong, B.K., Ehrnhoefer, D.E., Graham, R.K., et al. Partial rescue of some features of Huntington disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol Dis 76 (2015), 24–36.
182. Xu, Q., Huang, S., Song, M., et al. Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms. J Cell Biol 202 (2013), 1123–1138.
183. Yamamoto, A., Lucas, J.J., Hen, R., Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000), 57–66.
184. Yanai, A., Huang, K., Kang, R., et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 9 (2006), 824–831.
185. Yang, S.H., Li, W., Sumien, N., et al. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: methylene blue connects the dots. Prog Neurobiol S0301–0082:15 (2015), 30060–30065.
186. Young, A.B., Huntingtin in health and disease. J Clin Invest 111 (2003), 299–302.
187. Zala, D., Colin, E., Rangone, H., et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17 (2008), 3837–3846.
188. Zala, D., Hinckelmann, M.V., Yu, H., et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 152 (2013), 479–491.
189. Zhang, Q.C., Yeh, T.L., Leyva, A., et al. A compact beta model of huntingtin toxicity. J Biol Chem 286 (2011), 8188–8196.
190. Zheng, Z., Li, A., Holmes, B.B., et al. An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J Biol Chem 288 (2013), 6063–6071.
191. Zourlidou, A., Gidalevitz, T., Kristiansen, M., et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet 16 (2007), 1078–1090.
192. Zu, T., Liu, Y., Banez-Coronel, M., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 110 (2013), E4968–E4977.
193. Zuccato, C., Cattaneo, E., Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5 (2009), 311–322.
194. Zuccato, C., Cattaneo, E., Huntington's disease. Handb Exp Pharmacol 220 (2014), 357–409.